Shares of nano cap Rosetta Genomics (ROSG +15.2%) pop 11% on twice normal volume.
Company reports the publication of a study suggesting the predictive role of miRNA's in platelets in chronic heart failure patients with atrial fibrillation (AF). The results revealed a 3.2-fold lower miR-150 expression in the platelets of patients with AF compared to those without AF. Patients with AF generally have poor prognoses.
The use of miRNA biomarkers in the management of heart disease is a major research area for Rosetta. It plans to launch an AF assay in 2017.